ESPE Abstracts (2019) 92 P1-138

ESPE2019 Poster Category 1 Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology (22 abstracts)

Changes in Body Mass Index in Boys with Central Precocious Puberty During and After Gonadotropin-Releasing Hormone Agonist Treatment

Chang Dae Kum 1 , Jung Gi Rho 1 , Kyung In Lim 2 , Jung Sub Lim 3 , Hae Sang Lee 1 & Jin Soon Hwang 1

1Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea, Republic of. 2Department of Pediatrics, Gachon University Gil Medical Center, Inchon, Korea, Republic of. 3Department of pediatrics, Korea Cancer Center Hospital, Seoul, Korea, Republic of

Background: Gonadotropin-releasing hormone agonist (GnRHa) treatment is widely used for central precocious puberty (CPP). Although some authors found increases in body mass index (BMI) in girls after GnRHa treatment, most studies reported no significant difference in BMI in girls during and after treatment. However, few studies have investigated changes in BMI in boys with CPP during and after GnRHa treatment. Hence, we aimed to evaluate the effects of GnRHa treatment on BMI in boys diagnosed with CPP.

Methods: This study included 75 boys who had been diagnosed with CPP at Ajou University Hospital between January, 2007 and December, 2016, and treated with leuprorelin acetate or triptorelin acetate every 4 weeks for at least 2 years. CPP was defined as the development of pubertal symptoms such as testicular volume ≥ 4cc before the age of 9 years, bone age advanced at least 1 year beyond chronological age, and a pubertal response to a GnRH stimulation test (peak luteinizing hormone response ≥5 IU/L). The subjects were divided into three groups according to BMI: normal weight, overweight, and obese. We analyzed the BMI standard deviation score (SDS) in each group before treatment, after 1 and 2 years of treatment, at the end of treatment, and at 6 months of follow-up.

Results: Of the 75 boys, 37 were in the normal weight group, 21 were in the overweight group and 17 were in the obese group; 25 of the boys were followed up for at least 6 months after treatment (11 in the normal weight group, 9 in the overweight group, 5 in the obese group). All underwent brain MRI before treatment began, and 9 boys showed abnormal MRI findings. The mean BMI SDS for all boys at initiation of treatment was 1.0±0.8, and the BMI SDS in the normal weight, overweight, and obese group were 0.3±0.4, 1.3±0.1, and 1.9±0.3, respectively. Compared to the values before treatment, there were no significant differences in the BMI SDS in all patient groups after 1 or 2 years of treatment. Moreover, for the boys who were followed up for at least 6 months, none of the patient groups showed any significant differences in the BMI SDS before treatment, at the end of treatment, or at 6 months after the end of treatment.

Conclusion: The BMI SDS in boys with CPP did not significantly change during GnRHa treatment and after the end of treatment.

Volume 92

58th Annual ESPE

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.